RE: A Very Very Positive Buy31 Oct 2022 18:57
there is absolutely nothing wrong in changing the final dosage
at this critical stage before approval, and ultimately coming to Market,
if the FDA recommend it, NP'' STOP BEEN AN A--SS nit picking
asking me about other CO in p3'' you sound like you know more than the FDA LOL!!
and we all know where the SP drop from, there is no need to go on about it as the recovery
is all that matters.
anyway, there is lots of big pharma company out there, that's in P3 for something
and is still working on the final dosage to get approval, and the FDA is not giving them any
significant guidance to get them through? IMM is perhaps a one off, that means it must be very close
and the FDA already knows that it works. and a higher dosage would make it a lot more effective
than it already is ATM, which is not a bad thing, if lesson is to be learnt from the COVID 19 vaccine
and the rush to Market in a year with efficacy unknown, leaving a lot of people with blood clot
and other problem Inc death
GSK bought sierras for its P3 for $1.9b, and still have work to do
before it comes to market? BMS tried for years to get there P3 TYK2 to Market
failed 3 times, and only just got approval 2 month ago I could go on, but I won't
as arguing the toss is always disruptive,
good day to you sir